Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
Agenus (NASDAQ: AGEN) announced that Dr. Steven O’Day and Dr. Dhan Chand will participate in a fireside chat hosted by B. Riley on November 15, 2021, at 12:00 PM EST. The discussion will focus on the AGEN1181 program, an Fc-enhanced CTLA-4, following the presentation of clinical data at the Society for Immunotherapy of Cancer's 36th Annual Meeting on November 12, 2021. Registration for the webinar is available online, with a replay to be accessible on the company's Events & Presentations page post-call.
Agenus specializes in immuno-oncology with a focus on therapies to combat cancer.
- None.
- None.
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery at Agenus, will participate in a fireside chat hosted by B. Riley on Monday, November 15, 2021 at 12:00 PM EST. Dr. O’Day and Dr. Chand will discuss the AGEN1181 program (Fc-enhanced CTLA-4), following presentation of clinical data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on Friday, November 12th, 2021.
Registration for the webinar can be done in advance at: https://www.webcaster4.com/Webcast/Page/2433/43588.
A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its affiliate MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of therapeutic candidates AGEN 1181, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of the therapeutic candidates, both alone and in combination with each other and/or other agents; future clinical and regulatory development plans for AGEN1181; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Agenus Inc.
Divya Vasudevan, PhD
781-674-4571
divya.vasudevan@agenusbio.com
Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
What is the date of the fireside chat involving AGEN1181?
Who will represent Agenus in the B. Riley fireside chat?
What will be discussed in the fireside chat about AGEN1181?
Where can I register for the Agenus webinar?
When will the clinical data for AGEN1181 be presented?
